0001133416-23-000063.txt : 20230717 0001133416-23-000063.hdr.sgml : 20230717 20230717080212 ACCESSION NUMBER: 0001133416-23-000063 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230714 FILED AS OF DATE: 20230717 DATE AS OF CHANGE: 20230717 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEWIS JOEL CENTRAL INDEX KEY: 0001725595 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 231090551 MAIL ADDRESS: STREET 1: 12575 ULINE DRIVE CITY: PLEASANT PRAIRIE STATE: WI ZIP: 53158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 BUSINESS PHONE: 678-620-3186 MAIL ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 4 1 form4.xml X0508 4 2023-07-14 0001133416 GALECTIN THERAPEUTICS INC GALT 0001725595 LEWIS JOEL C/O GALECTIN THERAPEUTICS INC. 4960 PEACHTREE INDUSTRIAL BLVD., STE 240 NORCROSS GA 30071 true true President and CEO false Common Stock 2023-07-14 4 A 0 11820 1.63 A 922562 D Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units ("DSUs") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024. Represents shares underlying DSUs and Common Stock. Jack W. Callicutt, by power of attorney 2023-07-17